Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Interested in hosting an Oncology Best Practice™ program at your institution? Contact Sara Shaughnessy at Sshaughnessy@gotoper.com or call (609) 378-3701.
Oncology Best Practice™:
Optimizing Outcomes when Quality Is Being Measured: A Focus on Evidence-Based Care for Gastric and Gastroesophageal Junction Cancer Treatment
April 2017-June 2018
In patients with advanced gastric cancers, novel strategies across multiple lines of therapy can be personalized based on tumor characteristics. Other approaches can offer options to patients that may mitigate toxicity by obviating the need for more toxic therapies. Knowledge of key trials should inform clinical decision making and allow for optimized treatment sequencing and proactive mitigation of predictable treatment-related toxicities for patients with these most difficult-to-treat solid tumors.
Accordingly, there is a need for educational activities targeted to community practitioners that illustrate how to consider and apply key data sets in the context of the real world scenarios these clinicians routinely encounter in their practice settings. To meet these educational needs, this series of programs has recruited national experts who can synthesize data sets on newly available and late-stage investigational strategies to manage advanced gastric cancers and can assist community practitioners in optimizing outcomes for their patients.
Key Topics to be Addressed
- Choosing the optimal therapy for patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancers
- Managing toxicities common to standard therapeutic regimens
- Emerging targeted therapies for gastric and GEJ cancers, including HER2-targeted agents, EGFR-targeted agents, and immunotherapy agents
- The potential for personalized therapy using gene expression profiling
This activity is directed toward community oncologists, nurses, and pharmacists who treat or manage patients with gastric cancer or gastroesophageal junction cancers. Fellows, nurse practitioners, physician assistants, researchers, and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.
In order to request this CME/CE-certified activity for your center, please contact Sara Shaughnessy at Sshaughnessy@gotoper.com
Upon completion of this activity, participants will be better prepared to:
- Discuss current evidence-based recommendations and quality measures for the management of locally advanced and metastatic gastric and gastroesophageal junction (GEJ) cancers
- Evaluate the efficacy and safety profiles of current and emerging therapies for locally advanced and metastatic gastric and GEJ cancers
- Individualize treatment by optimizing treatment sequencing and the management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ cancers
- Apply clinical trial data for first- and second-line therapies for locally advanced or metastatic gastric and GEJ cancers
Activity ChairpersonManish A. Shah, MD
Bartlett Family Associate Professor of Gastrointestinal Oncology
Co-Director, Center for Advanced Digestive Care
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Weill Cornell Medical College/New York-Presbyterian Hospital
New York, NY
April 29, 2017
New York, NY
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary Cancers
Apr 29, 2017